P. Broet et al., Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial, BREAST CANC, 58(2), 1999, pp. 151-156
A potential advantage of primary over adjuvant chemotherapy in breast cance
r survival had been proposed on theoretical grounds. In 1994, early results
of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy f
or operable breast cancer in 390 premenopausal patients had shown significa
nt improvement in survival of the primary chemotherapy arm (p=0.04). An upd
ated analysis conducted in 1995 showed the disappearance of this difference
between the two arms (p=0.18).
In the present analysis, we investigated the potential short and long-term
benefits attributable to primary chemotherapy by applying weighted logrank
tests designed to assess specifically these effects. Results were compared
to those obtained with the classical logrank test.
At a median follow-up of 105 months, a significant short-term survival bene
fit (p=0.02) in favor of the primary chemotherapy has been shown. However,
no long-term survival benefit (p=0.36) could be documented. The classical l
ogrank test had revealed no significant difference (p=0.24) between the two
groups but the proportional hazard assumption being rejected (p=0.04), the
efficiency of this test can be questioned.
Results using the present analysis suggested that primary chemotherapy dela
yed early death rates, without significantly modifying long-term event rate
s. It emphasizes that a short-term effect which is not necessarily associat
ed with a long-term benefit may be seen at an early evaluation and disappea
r later on.